Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology Network
Hematologic Oncology Update
00:00
Overview of current CLL treatment options
Kerry A Rogers outlines three frontline approaches: continuous BTK inhibitors, venetoclax‑based fixed duration, and BTK+venetoclax combos.
Play episode from 01:29
Transcript
